Mesoblast Q1 Ryoncil Revenue Rises 44% to $28M
Mesoblast reported Q1 Ryoncil revenue of $28M, up 44% year over year. Operating cash spend was $2.1M, an 86% improvement, and cash totaled $99M as of September 30, 2026. The company also completed treatment in a Phase 3 CLBP trial and aligned with the FDA on a BLA filing for LVAD GI bleeding.